Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study

• Published in: Supportive care in cancer 2022-07, Vol.30 (7), p.6225-6232
• Main Authors: Gao, Jiali, Zhao, Jun, Jiang, Caihong, Chen, Feng, Zhao, Lanzhen, Jiang, Ying, Li, Hui, Wang, Wenjuan, Wu, Yungaowa, Jin, Yilan, Da, Lenggaowa, Liu, Guang, Zhang, Yajuan, Li, Hongxia, Zhang, Zewei, Jin, Gaowa, Li, Quanfu
• Format: Article
• Language: English
• Subjects: Antiemetics; Antiemetics - therapeutic use; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antipsychotics; Aprepitant; Aprepitant - therapeutic use; Cancer; Care and treatment; Chemotherapy; Cisplatin - adverse effects; Clinical trials; Dexamethasone; Dexamethasone - therapeutic use; Humans; Medicine; Medicine & Public Health; Nausea; Nausea - chemically induced; Nausea - drug therapy; Nausea - prevention & control; Nursing; Nursing Research; Olanzapine; Olanzapine - therapeutic use; Oncology; Original; Original Article; Pain Medicine; Palonosetron; Prevention; Prospective Studies; Quality of Life; Rehabilitation Medicine; Side effects; Tropisetron - therapeutic use; Vomiting; Vomiting - chemically induced; Vomiting - drug therapy; Vomiting - prevention & control
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-022-07067-6

Objective A prospective randomized controlled trial was conducted to compare 5 mg olanzapine plus standard triple antiemetic therapy for the prevention of nausea and vomiting induced by multiple-day cisplatin chemotherapy. Methods Patients who received a 3-day cisplatin-based chemotherapy (25 mg/m 2 /d) were given either 5 mg olanzapine plus triple therapy with aprepitant, tropisetron, and dexamethasone (quadruple group) or 5 mg olanzapine plus tropisetron and dexamethasone, omitting aprepitant (triplet group). The primary endpoint was the complete response (CR) in the overall phase (OP) (0–120 h) between quadruple group and triplet group. The secondary endpoints were the CR in the acute phase (AP) (0–24 h) and delayed phase (DP) (25–120 h) between two groups. The first time of vomiting was also compared by Kaplan–Meier curves. The impact of chemotherapy-induced nausea and vomiting (CINV) on the quality of life was assessed by the Functional Living Index-Emesis (FLIE). Aprepitant-related adverse effects (AEs) were also recorded. Results (1) The primary endpoint CR during OP was 76.0% (45/59) vs 67.0% (41/61) between the quadruple group and triplet group ( P  = 0.271). The secondary endpoint CR during the AP was significantly higher in the quadruple group than in the triplet group, which was 100.0% (59/59) vs 93.0% (57/61) ( P  = 0.045). The difference of CR during delayed phase between the groups was especially higher in the quadruple group compared to the triplet group (76.0% (45/59) vs 67.0% (41/61) ( P  = 0.271)). The rate of patients who achieved total protection in the overall phase was also higher in the quadruple group than the triplet group (28.8% (17/59) vs 23.0% (14/61) ( P  = 0.463)). During the OP, the incidence of no vomiting in the quadruple group and the triplet group was 93.2% (55/59) vs 80.3% (49/61) ( P  = 0.038), respectively. (2) Kaplan–Meier curves of time to first emesis were obviously longer in the quadruple group compared with the triplet group ( P  = 0.031). According to FLIE, no impact of CINV on daily life was defined as total score of questionnaire > 108; this study exhibited identical life quality between two groups. (3) The most common aprepitant- or olanzapine-related AEs included sedation, fatigue, and constipation. The occurrences between two groups were identical. Conclusion It may been recommended that 5 mg olanzapine plus tropisetron and dexamethasone, omitting aprepitant triplet regimen as an alternative therapy in prev